Chemotherapy has represented the standard therapy for unresectable or metastatic urothelial carcinoma for more than 20 years. The growing knowledge of the interaction between tumour and immune system has led to the advent of new classes of drugs, the immune-checkpoints inhibitors, which are intended to change the current scenario.
INTRODUCTION
Urothelial cancer of the bladder, renal pelvis, ureter and other urinary organs is the most common malignancy involving the urinary system and the ninth most common malignancy worldwide, with about 430000 new cases diagnosed in 2012 [1] .
In metastatic or unresectable disease, Cisplatin combination regimens have represented the standard First line therapy for patients with good performance status while patients unfit to Cisplatin were generally treated with Carboplatin regimens or platinum-free combinations containing taxanes and gemcitabine with an Overall Survival (OS) benefit achieved of 14 months [2] [3] [4] [5] .
After progression to first line several drugs have been tested without significant improvement in mOS except for Vinfluine, which showed an OS benefit only in eligible patients population compared to best supportive care in a phase III trial [6, 7] .
From more than 20 years no active treatments have shown to improve clinical outcome of patients with UC compared to chemotherapy. This until the demonstration that bladder cancer, like melanoma and non small cell lung cancer, is a tumour with a high somatic mutation frequencies and a high antigenic expression resulting in an optimal target for immune-checkpoint inhibitors [8] .
PD-1 and PD-L1 are members of the Ig superfamily expressed on hematopoietic and nonhematopoietic cells (PD-L1) as well as on T Cell surface (PD-1). PD-L1/PD-1 interaction leads to ''T-Cell exhaustion'' that consisted of impaired cytotoxic activity and decreased effector cytokine production resulting in immune-response inhibition.
Atezolizumab (MPDL3280A) is an engineered, humanised monoclonal IgG1 antibody, with a high affinity for PD-L1 acting as inhibitor of the interaction between PD-L1 and PD1/B7.1. It was the First immune agents who showed clinical activity in UC [9] . On the wave of the positive results obtained in phase I trial, a following phase II trial (IMvigor 210 trial, NCT02108652) with two different cohorts was performed (cohort 1, patients with metastatic urothelial cancers ineligible for platinum based chemotherapy for First line treatment; cohort 2, patients who progressed during or 4 following platinum-based treatment). Regarding, Cohort 2 (n=310), patients who received Atezolizumab showed an Objective Response Rate (ORR) of 15% and a 12-month OS of 37% in the overall population with a median duration of response not reached after a medium of 17.5 months of follow-up [10] .
Results of Cohort 1 (n=119) showed an ORR of 23% in the whole cohort with a median duration of response not reached at 14.4 months of follow-up and a median OS of 14.8 months (95% CI 10.1 months to not reached) [11] .
On the basis of the favourable results of the cohort 2, Atezolizumab has been approved by FDA for the treatment of patients with locally advanced or metastatic UC who have progressed during or following platinum-based chemotherapy or whose disease has worsened within 12 months neoadjuvant or adjuvant platinum-based chemotherapy.
Despite these remarkable results, more recently Powees et al recently presented preliminary results of IMvigor211. This was a randomized phase III trial of Atezolizumab compared to chemotherapy (docetaxel, paclitaxel and vinflunine) in patients progressed to platinum based therapy. Surprisingly Atezolizumab failed to show an improvement in Overall Survival in overall population (8.6 vs 8.0 months for Atezolizumab and chemotherapy respectively, HR 0.85) and in patients with high PD-L1 expression (11.6 vs 10.6 months, HR 0.87) [12] .
Pembrolizumab (MK-3475) is a humanized monoclonal IgG4 antibody against PD-1, which showed to be a safety and active treatment in a phase I basket trial involving also patients with UC [13] . Thanks to the positive results obtained in this study Pembrolizumab has been compared to standard second line chemotherapy in a large phase III clinical trial (Keynote 045) [14] . In this study 542 patients with locally advanced or metastatic predominantly transitional UC, progressed to Partial results of the still ongoing phase II KEYNOTE 052 trial seems to confirm this positive results also when Pembrolizumab is adopted as First line therapy in platinum unfit patients with UC [15] .
Nivolumab (MDX 1106) is a fully human IgG4 monoclonal antibody against PD-1 that has been approved for treatment of advanced melanoma, Hodgkin lymphoma, non-small cell lung cancer, head and neck cancer, and renal cell cancer. In UC it showed to be an active and safety treatment in phase I and II studies [16, 17] . As observed with Nivolumab also the PD-L1 inhibitors Avelumab (MSB0010718C) and Durvalumab (MEDI4736) showed promising activity in phase I/II clinical trials in patients with UC suggesting the development of further clinical trials exploring these agents in different setting of UC [18] [19] [20] [21] . The CTLA-4 receptor also known as CD156 is a member of the immunoglobulin superfamily and a transmembrane receptor expressed exclusively on T cells.
The activation of CTLA-4 happened through interaction with CD80 and CD86 on antigen presenting cells and leads to a down-regulation of T helper lymphocyte and enhanced regulatory T cell immunosuppressive activity resulting in immune response inhibitor signal [22] .
Ipilimumab is a CTLA-4 inhibitor that showed in a small clinical trial to be a safety preoperative treatment in patients with bladder UC [23] .
On the basis of the positive outcome obtained it seems clear that the treatment paradigm of UC is about to change. The demonstration that immunotherapy could led to long term responses in different setting of UC and the safety profile showed in different clinical trials have move the development of several studies exploring these agents. This has led to in a complex scenario that will profoundly change the management of the disease. In the next paragraphs we will describe the 6 ongoing and active clinical trials exploring these agents in different setting of the disease. In table 1 and table are summarized the phase III and phase I, I/II, II descripted in this manuscript. 
PD-1 AND PD-L1 INHIBITORS

EHNANCING IMMUNOTHERAPIES THROUGH COMBINATION STRATEGIES
As already discussed, not all subjects respond to immune-checkpoint inhibitors and so the development of new strategies aimed to increase the number of patients who can benefit from these treatments it's strictly required.
There are several evidences showing that previously inflamed tumour could more benefit from immune-checkpoints inhibitors while "no-T cell inflamed tumours" not [24] [25] [26] 
PD-1/PD-L1 and CTLA-4 inhibitors combination
As already descripted, PD-L1/PD-1 and CTLA-4 inhibitors adopt a different mechanism to enhance immune response against tumours. Indeed, inhibition of PD-L1/PD-1 pathway lead to a restored activity of pre-activated exhausted T cells while inhibition of CTLA-4 receptors resulting in an effector T Cell amplification in early stages of antigen presentation. As these are different pathway of a common cascade resulting in T Cell activation, a dual immune-checkpoint blockade could be a key option that would allow reaching better clinical outcome than PD-L1/PD-1 or CTLA-4 monotherapy. This combination strategy has been already tested in melanoma with significant improvement of long-term responses compared to single agent monotherapy [27, 28] . The Nivolumab and Ipilimumab combination is currently being tested in a large randomized clinical trial where patients with untreated metastatic or unresectable UC will be randomized to receive the immune checkpoints combination or platinum based chemotherapy (NCT03036098; CheckMate 901). The estimated enrolment of this trial is 690 patients with PFS and OS as primary endpoint.
Another large phase II clinical trial (NCT01928394) is currently comparing the Nivolumab and ipilimumab association to Nivolumab monotherapy in patients with advanced triple-negative breast cancer, gastric cancer, pancreatic adenocarcinoma, small cell lung cancer, bladder cancer, and ovarian cancer. 
Immune-checkpoint inhibitors and other immune agents
Another interesting strategy aimed to enhance the therapeutic potential of immune-checkpoint inhibitors consists of a combination between these agents and other able to increase the tumour associated immune-stroma. BCG instillation is able to induce an immune response against tumour cells and it's currently approved in early stage of urothelial bladder cancer with high risk of recurrence after local resection [29] . The association between BCG acting as an immune cells The association between PD-L1 and PD-1 inhibitors is another option under investigation. Indeed, an ongoing phase 1 open-label (NCT02118436), dose-escalation and expansion study is recruiting patients with relapsed/refractory advanced solid malignancies to receive Durvalumab in combination to MEDI0680, a humanized IgG4κ monoclonal antibody specific for human PD-1 that blocks interaction with PD-L1 and programmed cell death ligand-2 (PD-L2). Of note, preliminary results showed a 15% ORR and a 35% DCR. The most common drug-related adverse events were pruritus (17%), fatigue (13%), diarrhoea (13%), flushing (10%), peripheral edema (10%) and pyrexia (10%) [39] .
Immune-checkpoint inhibitors and oncolytic viruses
Oncolytic viruses are novel promising agents against cancer. These modified viruses could be directed against specific targets, perform a lytic effect on tumour cells and act as immune stimulators [40, 41] . Thanks to these proprieties, oncolytic viruses are currently testing in several clinical trials. Regarding UC, CA21 and enadenotucirev are currently under evaluation. The oncloytic coxsackievirus CA 21 target the Intercellular Adhesion Molecule I (ICAM-1) on tumour cells surface. It has already showed promising activity in melanoma as well as in non muscular invasive bladder cancer [42, 43] . To date the safety of combination between pembrolizumab and CA21 in advanced or recurrent tumours is being evaluated in phase I clinical trial (NCT02043665).
Enadenotucirev is an oncolytic group B adenovirus able to replicate in cancer cells leading to their lysis. It showed a safety profile in patients with metastatic epithelial cancer [44] and is currently tested with Pembrolizumab in metastatic solid tumours (NCT02636036).
Immune-checkpoint inhibitors combination and chemo/radio therapy
Radiotherapy and chemotherapy could play a key role as agents able to overcome immune-tumour escape. Indeed, tumour irradiation stimulates an intensive inflammation in the site of application, promotes the production of adhesion molecules and MHC I and activates an intensive flux of CD8+ lymphocytes. Through these mechanisms irradiation drives an immune response that leads also to the regression of distant and un-irradiated tumour lesions (Abscopal effect) [45, 46] . Not surprising, immune-checkpoint therapy combination with tumours irradiation represents an emerging strategy with a strong biological rational [46, 47] 
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The IMvigor130 (NCT02807636) is a randomized placebo-controlled phase 3 clinical trial where 1200 patients with metastatic or locally advanced unresectable urothelial cancer will be randomized to receive Atezolizumab (1200 mg every 3 weeks) alone or in combination with platinum based chemotherapy. Patients enrolled in comparator arm will receive standard platinum based chemotherapy with placebo. This study will test safety and the clinical efficacy of Atezolizumab monotherapy or combination with primary endpoints PFS, OS and adverse events rate. The estimated primary completion data is expected in December 2018 while the completion of study in July 2020. The phase Ib NCT02546661 is a randomised multi-drug trial testing the PD-L1 inhibitor Durvalumab, the nuclear enzyme poly (ADP-ribose) polymerase (PARP) Olaparib, the mammalian target of rapamycin (mTOR) inhibitor Vistusertib, the FGFR inhibitor AZD4547 and the WEE1 tyrosine kinase inhibitor AZD1175. This study is evaluating the safety profile of these association and has an estimated enrollment of 110 patients with muscle invasive bladder cancer progressed on prior treatment who will be randomized to receive: AZD4547, Durvalumab with AZD4547, Durvalumab with Olaparib, Durvalumab with AZD1775, Durvalumab with Vistusertinib or Durvalumab monotherapy.
Immune checkpoint inhibitors combination with target therapy
Another interesting agent under inverstigation is Vorinostat that is a compound able to bind the catalytic domain of the histone deacetylases resulting in accumulation of hyperacetylated histones and trascription factors [53] . Hyperacetylation of hystone results in upregulation of cyclindependant kinase p21 and in a G1 arrest of the cell cycle. Furthermore, hyperacetylation of nonhistone proteins such as p53, alpha tubulin and heat-shock protein 90 leads to an additional antiproliferative effect. A phase I/II study is evaluating the safety profile and the clinical activity of the association between Pembrolizumab and Vorinostat in previously treated patients with advanced or metastatic renal cell carcinoma and UC (NCT02619253).
OTHER IMMUNOLOGICAL APPROACH
Interleukin-15 is a cytokine who plays a key role in activation, development and proliferation of CD8+ Memory T cells and natural killer cells. ALT-803 is a IL-15 mutant able to enhance activity that has demonstrated safety and promising anti-tumour activity in solid and haematological tumour models [54, 55] . Several trials are currently testing this agent in combination with BCG in high risk not muscle invasive bladder cancer (NCT03022825, NCT02138734).
ALT-801 is a novel immunotherapeutic fusion protein composed of interleukin-2 linked to a single chain T cell receptor domain who has already shown to be a safety and active treatment against solid and haematological malignancies [56, 57] . Furthermore, ALT-801 has been tested with platinum based chemotherapy in patients with advanced or metastatic UC showing an interesting ORR (35%) burdened by a significant toxicity (50% of patients with Grade 3-4 adverse related events) [58] . Future trials will explore the role of this agent in UC (NCT01625260, NCT01326871).
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CD137 is a costimulatory member of the TNF (Tumour Necrosis Factor) receptor superfamily that is expressed on T Cells, dendidritc cells and natural killer cells after antigen mediated activation.
CD137 activation results in cytokine induction and stimulated activity of T-Cells leading to an enhanced immune-response against tumour cells [59, 60] . Urelumab (BMS-663513) is a fully human IG4 antibody able to blind and agonist CD137 receptor has already been tested in small phase I clinical studies showing a safety profile [61] . A phase II clinical trial (NCT02845323) will compare this combination treatment to Nivolumab monotherapy as neo-adjuvant treatment in patients unfit to Cisplatin standard therapy.
CD27 is another costimulatory receptor member of the TNF receptor superfamily. CD27, which through the interaction with its ligand (CD70), plays an important role in generation and maintenance of immune response especially through B-Cell activation and immunoglobulin synthesis [62] . Varlilumab is a human monoclonal antibody with agonistic activity to CD27 receptor that is currently testing with Atezolizumab in a phase I clinical trial exploring the safety profile and the clinical activity of this combination (NCT02543645) [63] .
B7-H3 belongs to B7 superfamily and acts a costimulatory molecule who leads after itself stimulation to a down-modulation of T-Cell activation [64] This molecule has been recently associated with specific immune-pathways and poor clinical outcome in prostate cancer [65] . There are further evidences that the depletion of arginine in arginase-expressing myeloid cells leads to an inhibition of proliferation and activity of lymphocytes resulting in an immune-response inhibition [68] . To overcome the immunosuppressive effect caused by arginine depletion a human arginases inhibitor has been developed. A phase I trial (NCT02903914) is currently testing the safety profile of the arginases inhibitor CB-1158 alone or in combination with Nivolumab in 236 patients with advanced solid malignancies including UC.
The adenosine A2A receptor also known as ADORA2A is an adenosine receptor expressed basal ganglia, vasculature, and platelets. Several immune cells like macrophages, dendritic cells, natural killer cells and T-lymphocites expressed this receptor whose activation leads to an inhibition of the immune response [69] . CPI-444 is a small molecule that acts as an antagonist of Adenosine A2A 18 receptor. It's safety profile in combination with Atezolizumab is currently under investigation in patients with advanced solid tumours including also patients with UC (NCT02655822).
FUTURE PERSPECTIVES
Chemotherapy has represented the standard treatment for locally advanced and metastatic UC but this scenario is about to change. The important results achieved suggesting that immunotherapy will probably be the future treatment paradigm of the disease. Immune-checkpoint inhibitors represent a realistic hope for patients with UC. Indeed, they appear to significantly improve the overall survival of these patients and thanks to a better safety profile compared to chemotherapy they could be proposed also in patients with poor clinical features.
Future trial will explore the role of immune-checkpoint inhibitor in other setting of the disease including: early stages, pre-operative and adjuvant setting and their efficacy as First line treatment.
Furthermore, another issue to be explored is whether combination between immune-checkpoint inhibitors and other agents including other immune-agents, target drugs, oncolytic viruses, chemotherapy and radiotherapy leads to a high percentage of patients who can benefit from immunotherapy. The possibility that several patients could obtain stable and durable response have lead to the development of several clinical trials exploring different kind of combination between these agents boosting a revolution that has just begun.
CONCLUSION
Chemotherapy has represented the standard treatment for locally advanced and metastatic urothelial carcinoma but this scenario is about to change. The important results achieved suggesting that immunotherapy will probably be the future treatment paradigm of the disease. Immune-checkpoint inhibitors represent a realistic hope for patients with UC. Indeed, they appear to significantly improve the overall survival of these patients and thanks to a better safety profile compared to chemotherapy they could be proposed also in patients with poor clinical features.
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